Overview

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab
Tretinoin